Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index
Kefei Hu1, Saideh Berenjian1, Rolf Larsson2, Joachim Gullbo2, Peter Nygren3, Tanja Lövgren4, Bror Morein1
1Department of Medical Sciences, Section of Virology, Uppsala University, Uppsala, Sweden; 2Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden; 3Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Uppsala, Sweden; 4Department of Molecular Bioscience, Section for Veterinary Immunology and Virology, Swedish University of Agricultural Sciences, Uppsala, Sweden
Abstract: Saponin fractions of Quillaja saponaria Molina (QS) have cytotoxic activity against cancer cells in vitro, but are too toxic to be useful in the clinic. The toxic effect was abolished by converting QS fractions into stable nanoparticles through the binding of QS to cholesterol. Two fractions of QS were selected for particle formation, one with an acyl-chain (ASAP) was used to form killing and growth-inhibiting (KGI) particles, and the other without the acyl-chain (DSAP) was used to formulate blocking and balancing effect (BBE) particles. KGI showed significant growth inhibiting and cancer cell-killing activities in nine of 10 cell lines while BBE showed that on one cell line. The monoblastoid lymphoma cell line U937 was selected for analyzing the mode of action. Low concentrations of KGI (0.5 and 2 µg/mL) induced irreversible exit from the cell cycle, differentiation measured by cytokine production, and eventually programmed cell death (apoptosis). Compared to normal human monocytes, the U937 cells were 30-fold more sensitive to KGI. The nontoxic BBE blocked the cell killing effect of KGI in a concentrationdependent manner. In conclusion, the formulation of QS into nanoparticles has the potential of becoming a new class of anticancer agents.
Keywords: anticancer drug, Quillaja saponin, nanoparticle, apoptosis
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.